Fol­low­ing tie-up with Sanofi, transat­lantic AI firm se­cures lat­est Big Phar­ma deal in nine-fig­ure Bris­tol My­ers pact

More than six months af­ter se­cur­ing a nine-fig­ure deal with Sanofi for tar­get dis­cov­ery, a French AI re­search group has land­ed its next Big Phar­ma part­ner­ship.

Owkin, un­der the lead­er­ship of CEO Thomas Clozel, an­nounced Wednes­day morn­ing that it’s signed on with Bris­tol My­ers Squibb to op­ti­mize the Big Phar­ma’s clin­i­cal tri­als and im­prove the odds of clin­i­cal suc­cess, ini­tial­ly in car­dio­vas­cu­lar dis­ease. The an­nounce­ment comes af­ter a deal Owkin made with Sanofi last No­vem­ber that build on the pair’s pre­vi­ous dis­cov­ery col­lab­o­ra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER